文献速递头颈与中枢神经肿瘤

鼻咽癌治疗降阶梯策略综述

Treatment Deescalation Strategies for Nasopharyngeal Cancer: A Review.
PubMed 文献 · JAMA Oncol · 2020-12-23

本综述总结了鼻咽癌治疗降阶梯策略的现状,将降阶梯方法分为系统性治疗降阶梯和放疗降阶梯两类。综述讨论了在部分II期患者中豁免化疗,以及改变化疗方案、剂量和药物(从顺铂改为其他药物)的研究;放疗降阶梯涉及降低剂量和缩小治疗体积。许多策略以EB病毒DNA水平为指导,影像学标志物也显示出指导降阶梯的潜力。

要点

  • 降阶梯策略分为系统性治疗降阶梯和放疗降阶梯两类。
  • EB病毒DNA水平是指导降阶梯的稳健生物标志物。
  • FDG-PET和动态增强或弥散加权MRI等影像学标志物也显示潜力。

核心结论

  • 多种鼻咽癌降阶梯策略已被探索,大多数方法结局仍保持优异。
  • 患者选择仍是关键,长期结局和晚期并发症尚待确定。
  • 需要持续开展前瞻性、多中心研究以更好地个体化和降阶梯治疗。

研究设计与样本

  • 本综述基于文献回顾,总结了鼻咽癌降阶梯策略的现状。

主要发现

  • 降阶梯方法可分为系统性治疗降阶梯和放疗降阶梯两类。
  • 系统性治疗降阶梯包括在部分II期患者中豁免化疗,以及改变化疗方案、剂量和药物(从顺铂改为其他药物)。
  • 放疗降阶梯包括降低剂量和缩小治疗体积。
  • 许多策略以EB病毒DNA水平为指导,该标志物用于筛查、治疗监测和随访。
  • FDG-PET和动态增强或弥散加权MRI等影像学标志物也显示出安全指导降阶梯的潜力。

临床怎么用

  • 临床可考虑根据EB病毒DNA水平和影像学标志物选择适合降阶梯的患者。
  • 降阶梯策略需个体化,并关注长期结局和晚期并发症。

局限性

  • 长期结局和晚期并发症尚未确定。
  • 需要前瞻性、多中心研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Since the advent of modern radiotherapy techniques and incorporation of systemic chemotherapy for nasopharyngeal cancer, locoregional control has been excellent. However, the rate of treatment-related complications, many of which are irreversible, remains high. New approaches are being explored to determine whether the toxic effects of treatment can be relieved while maintaining disease control. This review presents the current state of deescalation strategies for nasopharyngeal cancer. OBSERVATIONS: A review of the literature shows that deescalation approaches can be generally categorized into deescalating systemic therapy vs deescalating radiotherapy. This review discusses studies that have explored sparing chemotherapy in selected patients with stage II cancer as well as altering the chemotherapy scheduling, dosing, and agent from the current standard of care, cisplatin. Deescalating radiotherapy has involved decreasing the dose and the treatment volume. In many cases, these approaches are being guided by measuring Epstein-Barr virus DNA levels, which is a robust biomarker for screening, treatment monitoring, and surveillance. Ongoing work with various imaging modalities, such as fluorodeoxyglucose positron emission tomography and dynamic contrast-enhanced or diffusion-weighted magnetic resonance imaging sequences, have shown promise as another biomarker to safely guide practitioners toward deescalation. CONCLUSIONS AND RELEVANCE: Various strategies to deescalate treatment in nasopharyngeal cancer have been explored, and outcomes have remained excellent in most approaches. Patient selection remains key, and long-term outcomes and late complications are still to be determined. Continued investigation with prospective, multi-institutional studies are needed to better elucidate how treatment for nasopharyngeal carcinoma can best be individualized and deescalated.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Lee A, Chow JCH, Lee NY, et al. Treatment Deescalation Strategies for Nasopharyngeal Cancer: A Review. JAMA Oncol. 2020. PMID: 33355642. doi:10.1001/jamaoncol.2020.6154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。